#31. A Phase I/II trial of ATI-2231 with Phase Ia in advanced soild tumor malignancies followed by Phase Ib/II in combination with capecitabine in patients with hormone receptor-positive (HR+) and HER2-negative metastatic breast cancer
Katherine Clifton,
Jingqin Rosy Luo,
Roberto Civitelli,
Stefanie Geisler,
Qamar Khan,
Ciara O'Sullivan,
Ajay Aggarwal,
Sheila Stewart,
Cynthia Ma
Affiliations
Katherine Clifton
Washington University School of Medicine, St. Louis, MO, USA
Jingqin Rosy Luo
Washington University School of Medicine, St. Louis, MO, USA
Roberto Civitelli
Washington University School of Medicine, St. Louis, MO, USA
Stefanie Geisler
Washington University School of Medicine, St. Louis, MO, USA
Qamar Khan
Washington University School of Medicine, St. Louis, MO, USA
Ciara O'Sullivan
Mayo Clinic, Rochester, MN, USA
Ajay Aggarwal
Washington University School of Medicine, St. Louis, MO, USA
Sheila Stewart
Washington University School of Medicine, St. Louis, MO, USA
Cynthia Ma
Washington University School of Medicine, St. Louis, MO, USA
